• Atara Biotherapeutics appointed Kevin G. Sarney as interim chief financial officer, effective June 26, 2026.
• Sarney, Life Science Practice Leader at Charles River CFO, will also serve as principal financial officer and principal accounting officer.
• He has more than 25 years of finance and accounting experience in life sciences, including prior executive finance roles and earlier work at PricewaterhouseCoopers.
• Chief Accounting Officer Yanina Grant-Huerta will leave the company effective July 17, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-285498), on June 26, 2026, and is solely responsible for the information contained therein.